Early anxiety prevention through a live, online group-based parenting program: Effectiveness in a randomized controlled trial.

Behav Res TherAug 11, 2026 (epub)
Clinical ResearchPsychiatry

Nina L Komrij, Frederike Y Scheper, Mia P Kösters et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the effectiveness of a live, online group-based parenting program for reducing anxiety symptoms in behaviorally inhibited children aged three to six years. A total of 148 parents participated, with results showing lower child anxiety symptoms in the intervention group compared to the control group at post-intervention (d = -.35) and follow-ups, although significance diminished by twelve months.

Key findings

  • Parents in the intervention group reported lower child anxiety symptoms at post-intervention (d = -.35).
  • At six-month follow-up, the effect size for reduced anxiety symptoms was d = -.46.
  • At twelve-month follow-up, the effect size remained at d = -.31, though not statistically significant.

Why it matters

Early intervention for anxiety in children is crucial for long-term mental health outcomes. This study highlights the potential of accessible online programs to support parents in managing anxiety symptoms in young children.

Source

PubMed · PMID 42600537

Published in Behav Res Ther. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.